Roche’s Cancer Drug Nears European Approval

The Committee for Medicinal Products for Human Use have approved of Roche’s cancer drug Tarceva, reports inpharm.com.

The CHMP expressed positive opinions about the drug as use as a first line treatment for patients with lung cancer. The daily, orally administered drug is already used as a second line treatment.

Roche’s head of global product development, Hal Barron, has said that the positive feedback “is an important step to bringing a personalised medicine option to people with lung cancer.” The use of the drug as a first line treatment is supported by two phase III trials which indicated Tarceva increased progression free survival compared to chemotherapy. The European Medicines Agency is expected to approve the drug in around three months.

Looking for a job in the pharmaceutical industry? Start by clicking here, now

Posted in: Industry News, News
CK Logo in place of featured image